Target intelligence / Profile preview

Renilla-luciferin 2-monooxygenase (RLuc)

Target
RLuc
Molecular classification
Enzyme, Oxidoreductase, Alpha/beta-hydrolase fold protein, Luminescent protein
01

Overview

Renilla-luciferin 2-monooxygenase (abbreviated as RLuc and also known as Renilla luciferase) is an enzyme originally isolated from the sea pansy *Renilla reniformis*, responsible for the blue light emission observed in this species[1][2][3][4][6][7]. The enzyme is a 36–37 kDa monomeric protein, structurally characterized by an alpha/beta-hydrolase fold and a conserved catalytic triad (Aspartic Acid 120, Glutamic Acid 144, and Histidine 285)[1][3][4][5][6][8]. RLuc catalyzes the oxidative decarboxylation of the substrate coelenterazine in the presence of molecular oxygen, yielding coelenteramide, carbon dioxide, and a photon of blue light (480 nm)[1][3][4][7]. In vivo, this blue light is transferred via resonance energy transfer to a green fluorescent protein (RrGFP), resulting in green bioluminescence[1][2][3].\nUnlike receptors or classical therapeutic targets, RLuc is not involved in normal human physiology or disease processes and is widely used in biotechnology as a genetic reporter in cell lines and animal models to quantify gene expression or to track biological processes by bioluminescence imaging[2][3][5][6]. There are no known drugs that modulate this enzyme for therapeutic purposes, and it does not serve as a biomarker or have direct disease associations.

Other names
Renilla luciferaseCoelenterazine h 2-monooxygenaseRenilla-type luciferase
02

Biological functions

BioluminescenceReporter gene/protein in molecular biologyIn vitro blue light emissionIn vivo green light emission via energy transfer

Beyond the preview

Go deeper on Renilla-luciferin 2-monooxygenase (RLuc).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Renilla-luciferin 2-monooxygenase (RLuc).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call